相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia
Robert J. Kreitman et al.
ONCOLOGIST (2020)
Ramucirumab: A Review in Hepatocellular Carcinoma
Yahiya Y. Syed
DRUGS (2020)
Atezolizumab for the treatment of breast cancer
Sangeetha M. Reddy et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study
Elliott Geoffrey Playford et al.
LANCET INFECTIOUS DISEASES (2020)
Antibodies to watch in 2020
Helene Kaplon et al.
MABS (2020)
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Steven G. Gray et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Vaccination Strategies and Immune Modulation of Atherosclerosis
Jan Nilsson et al.
CIRCULATION RESEARCH (2020)
COVID-19 and Cancer: a Comprehensive Review
Rohit Gosain et al.
CURRENT ONCOLOGY REPORTS (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Developing therapeutic monoclonal antibodies at pandemic pace
Brian Kelley
NATURE BIOTECHNOLOGY (2020)
IL-23 inhibitor guselkumab shows promise for PsA
Jessica McHugh
NATURE REVIEWS RHEUMATOLOGY (2020)
Machine Learning-Guided Prediction of Antigen-Reactive In Silico Clonotypes Based on Changes in Clonal Abundance through Bio-Panning
Duck Kyun Yoo et al.
BIOMOLECULES (2020)
Laboratory monitoring of hemophilia A treatments: new challenges
Peter J. Lenting
BLOOD ADVANCES (2020)
Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain
Joschka Bauer et al.
MABS (2020)
Biologics for the primary care physician: Review and treatment of psoriasis
Eric D. Schadler et al.
DM DISEASE-A-MONTH (2019)
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb
Andreas Wollenberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
The Increasingly Human and Profitable Monoclonal Antibody Market
Antonio L. Grilo et al.
TRENDS IN BIOTECHNOLOGY (2019)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
R. G. Langley et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Structural diversity and flexibility of diabodies
Na-Young Kwon et al.
METHODS (2019)
Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
Thomas Doerner et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
High-throughput retrieval of physical DNA for NGS-identifiable clones in phage display library
Jinsung Noh et al.
MABS (2019)
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study
Alice Bitossi et al.
MEDIATORS OF INFLAMMATION (2019)
Top drugs and companies by sales in 2018
Lisa Urquhart
NATURE REVIEWS DRUG DISCOVERY (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Five computational developability guidelines for therapeutic antibody profiling
Matthew I. J. Raybould et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues
Nazli Eda Kaleli et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2019)
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials
G. B. E. Jemec et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
Carmen F. Nobre et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service
Richard P. Gale et al.
EYE (2019)
Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules
Marcella Nebbioso et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing
Kothai Parthiban et al.
MABS (2019)
Non-Hodgkin lymphoma therapy landscape
Kritika Chaudhari et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia Sequist et al.
ONCOLOGIST (2019)
Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics
Esen Sokullu et al.
PHARMACEUTICS (2019)
Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials
Philip Mease et al.
ARTHRITIS CARE & RESEARCH (2019)
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
Diego Cadavid et al.
LANCET NEUROLOGY (2019)
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Zishuo Ian Hu et al.
CANCER MEDICINE (2019)
Current Clinical Trials in Pemphigus and Pemphigoid
Kentaro Izumi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis
Mounica Vallurupalli et al.
BLOOD (2019)
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects
Chiara Crotti et al.
DRUGS (2019)
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
Uqba Khan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies
Rajesh Kumar et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2019)
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Michael G. Hanna et al.
LANCET NEUROLOGY (2019)
Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus
A. Benitez et al.
LUPUS (2019)
Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies
Maxime Lecerf et al.
MOLECULAR IMMUNOLOGY (2019)
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
Patrizia Murer et al.
NEW BIOTECHNOLOGY (2019)
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Anna Wolska-Washer et al.
DRUG SAFETY (2019)
Necitumumab for the treatment of advanced non-small-cell lung cancer
Asuncion Diaz-Serrano et al.
FUTURE ONCOLOGY (2019)
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
David C. Smith et al.
INVESTIGATIONAL NEW DRUGS (2019)
Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J)
Y. Okubo et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Antibodies to watch in 2019
Helene Kaplon et al.
MABS (2019)
ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery
Philippe Valadon et al.
MABS (2019)
In vitro and in silico assessment of the developability of a designed monoclonal antibody library
Adriana-Michelle Wolf Perez et al.
MABS (2019)
Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI
Martina Schaefer et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study
David Jayne et al.
ARTHRITIS & RHEUMATOLOGY (2019)
GSK3196165 AN INVESTIGATIONAL ANTI-GM-CSF MONOCLONAL ANTIBODY, IMPROVES PATIENT REPORTED OUTCOMES IN A PHASE IIB STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
Chris Buckley et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficient Construction and Effective Screening of Synthetic Domain Antibody Libraries
Arghavan Solemani Zadeh et al.
METHODS AND PROTOCOLS (2019)
A review of avelumab in locally advanced and metastatic bladder cancer
Arpit Rao et al.
THERAPEUTIC ADVANCES IN UROLOGY (2019)
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib
Emily M. McWilliams et al.
BLOOD ADVANCES (2019)
Phage Display Libraries for Antibody Therapeutic Discovery and Development
Juan C. Almagro et al.
ANTIBODIES (2019)
Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections
Dana T. Lounder et al.
BLOOD ADVANCES (2019)
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Adam Bates et al.
ANTIBODIES (2019)
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial
Peter C. Taylor et al.
ARTHRITIS RESEARCH & THERAPY (2019)
BAY1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
Dirk Thomas et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Julio C. Chavez et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning
Mohamed A. Alfaleh et al.
ANTIBODIES (2019)
BEGONIA: Phase Ib/II open-label, platform study of safety and efficacy of durvalumab, paclitaxel and other novel oncology therapy agents as first-line (1L) therapy in patients with metastatic triple negative breast cancer (mTNBC)
P. Schmid et al.
CANCER RESEARCH (2019)
Retooling phage display with electrohydrodynamic nanomixing and nanopore sequencing
Lyndon J. Raftery et al.
LAB ON A CHIP (2019)
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB
Ingrid Teige et al.
FRONTIERS IN IMMUNOLOGY (2019)
CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2018)
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
The renaissance of complement therapeutics
Daniel Ricklin et al.
NATURE REVIEWS NEPHROLOGY (2018)
Product review on the Anti-PD-L1 antibody atezolizumab
Neil J. Shah et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
Kristine A. Smith et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2018)
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Silvia C. Formenti et al.
CLINICAL CANCER RESEARCH (2018)
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma
Martina Imbimbo et al.
CLINICAL LUNG CANCER (2018)
Belimumab: A Review in Systemic Lupus Erythematosus
Hannah A. Blair et al.
DRUGS (2018)
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
Eric Pujade-Lauraine et al.
FUTURE ONCOLOGY (2018)
Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study
Philip E. Silkoff et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Factor XIa Inhibitors as New Anticoagulants
Mimi L. Quan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Atul Deodhar et al.
LANCET (2018)
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Robert J. Kreitman et al.
LEUKEMIA (2018)
Healthcare utilisation prior to the diagnosis of inflammatory bowel diseases and the influence of livestock exposure: A longitudinal case-control study
Baukje J. van der Star et al.
PLOS ONE (2018)
Identification of high affinity HER2 binding antibodies using CHO Fab surface display
Annalee W. Nguyen et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2018)
Avelumab: A Review in Metastatic Merkel Cell Carcinoma
Matt Shirley
TARGETED ONCOLOGY (2018)
Basics of Antibody Phage Display Technology
Line Ledsgaard et al.
TOXINS (2018)
Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis A Randomized Clinical Trial
Tadashi Terui et al.
JAMA DERMATOLOGY (2018)
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Reynold A. Panettieri et al.
LANCET RESPIRATORY MEDICINE (2018)
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Juan C. Almagro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab
Andrew D. Cook et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan
Kyoko Ohno-Matsui et al.
EYE (2018)
Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Rimas V. Lukas et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi et al.
LANCET ONCOLOGY (2018)
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
Maria Quanz et al.
Oncotarget (2018)
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Jun Zhang et al.
FRONTIERS IN ONCOLOGY (2018)
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
Pamela Munster et al.
BRITISH JOURNAL OF CANCER (2018)
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks A Randomized Clinical Trial
Aleena Banerji et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cancer immunologists scoop medicine Nobel prize
Heidi Ledford et al.
NATURE (2018)
Biopharmaceutical benchmarks 2018
Gary Walsh
NATURE BIOTECHNOLOGY (2018)
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
Christophe Le Tourneau et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Third generation antibody discovery methods: in silico rational design
Pietro Sormanni et al.
CHEMICAL SOCIETY REVIEWS (2018)
DEKAVIL (F8IL10) - UPDATE ON THE RESULTS OF CLINICAL TRIALS INVESTIGATING THE IMMUNOCYTOKINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
M. Galeazzi et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy
Charles C. Wykoff et al.
OPHTHALMOLOGY RETINA (2018)
Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial
Adrian F. Ochsenbein et al.
BLOOD (2018)
Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC
N. Rizvi et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals
Tania Garito et al.
DIABETES OBESITY & METABOLISM (2018)
HER3 signaling and targeted therapy in cancer
Rosalin Mishra et al.
ONCOLOGY REVIEWS (2018)
LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
Shunji Takahashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer
Brant A. Inman et al.
CLINICAL CANCER RESEARCH (2017)
A comprehensive map of molecular drug targets
Rita Santos et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Novel TGF-β inhibitors ready for prime time in onco-immunology
Armand de Gramont et al.
ONCOIMMUNOLOGY (2017)
High-concentration protein formulations: How high is high?
Patrick Garidel et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2017)
The role of IL 23 in the treatment of psoriasis
Lluis Puig
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Pathogenesis of Hereditary Angioedema The Role of the Bradykinin-Forming Cascade
Allen P. Kaplan et al.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2017)
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
Su Jin Lee et al.
INVESTIGATIONAL NEW DRUGS (2017)
BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial
Francis H. Glorieux et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia
Lothar Seefried et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
Eileen Mary O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study
Daniel Rooks et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2017)
Phase lb Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results
Keunchil Park et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET (2017)
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
Diego Cadavid et al.
LANCET NEUROLOGY (2017)
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Christopher R. Heery et al.
LANCET ONCOLOGY (2017)
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L. Gulley et al.
LANCET ONCOLOGY (2017)
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer
Joerg Willuda et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
A. Banerji et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Biophysical properties of the clinical-stage antibody landscape
Tushar Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Aaron Simpson et al.
TARGETED ONCOLOGY (2017)
Amatuximab and novel agents targeting mesothelin for solid tumors
Paolo Baldo et al.
ONCOTARGETS AND THERAPY (2017)
Remembering Emil von Behring: from Tetanus Treatment to Antibody Cooperation with Phagocytes
Stefan H. E. Kaufmann
MBIO (2017)
Effect of DNA sequence of Fab fragment on yield characteristics and cell growth of E-coli
Antti Kulmala et al.
SCIENTIFIC REPORTS (2017)
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
Susanne Ostrowitzki et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Antibody Engineering for Pursuing a Healthier Future
Abdullah F. U. H. Saeed et al.
FRONTIERS IN MICROBIOLOGY (2017)
Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy
Daniel S. Rooks et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2017)
Atezolizumab for the treatment of non-small cell lung cancer
Fernando C. Santini et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Thrombotic thrombocytopenic purpura
Johanna A. Kremer Hovinga et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death
Marcus M. Fischer et al.
SCIENCE ADVANCES (2017)
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
Stina Wichert et al.
PLOS ONE (2017)
Rapid and accurate in silico solubility screening of a monoclonal antibody library
Pietro Sormanni et al.
SCIENTIFIC REPORTS (2017)
A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease
Andreas Eich et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2017)
New Opportunities and Challenges to Defeat Cancer Stem Cells
Erika K. Ramos et al.
TRENDS IN CANCER (2017)
B-cell-targeted therapies in relapsing forms of MS
Divyanshu Dubey et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)
A. Argiris et al.
ANNALS OF ONCOLOGY (2017)
Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning
Mohamed A. Alfaleh et al.
ANTIBODIES (2017)
Generation, Diversity Determination, and Application to Antibody Selection of a Human Naive Fab Library
Sangkyu Kim et al.
MOLECULES AND CELLS (2017)
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
Kerry Lynn Reynolds et al.
BMC CANCER (2017)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Flavio Vincenti et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges
Nikolaos Dervenis et al.
ADVANCES IN THERAPY (2017)
A Review of Ranibizumab for the Treatment of Diabetic Retinopathy
Michael W. Stewart
OPHTHALMOLOGY AND THERAPY (2017)
A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb) in patients with recurrent glioblastoma (GBM).
Lawrence Cher et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms
Daniel Bedinger et al.
MABS (2016)
Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study
Eric Sheldon et al.
ADVANCES IN THERAPY (2016)
PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)
D. Mahalingam et al.
ANNALS OF ONCOLOGY (2016)
Assessing the Immunogenicity of Biopharmaceuticals
Carlos Pineda et al.
BIODRUGS (2016)
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
Rupali Das et al.
BLOOD (2016)
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer
Kathy Miller et al.
BMC CANCER (2016)
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
E. Elez et al.
BRITISH JOURNAL OF CANCER (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
Muhammad Wasif Saif et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
Anette Sommer et al.
CANCER RESEARCH (2016)
A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and-2 Inhibitor, in Patients with Advanced Solid Tumors
Afshin Dowlati et al.
CLINICAL CANCER RESEARCH (2016)
Merkel Cell Carcinoma Therapeutic Update
Nicole M. Cassler et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Novel therapeutic options for cachexia and sarcopenia
Alessio Molfino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Peng Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Phage display-derived human antibodies in clinical development and therapy
Andre Frenzel et al.
MABS (2016)
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Magdalena Malm et al.
MABS (2016)
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Flora Peyvandi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The diversity of H3 loops determines the antigen-binding tendencies of antibody CDR loops
Yuko Tsuchiya et al.
PROTEIN SCIENCE (2016)
First-line Treatment for advanced Renal Cell Carcinoma A Phase 3, open-label, randomized Study of Atezolizumab (Anti-PD-L1-Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with untreated advanced Renal Cell Carcinoma (IMmotion) AN 37/15 of AUO
H. Rexer et al.
UROLOGE (2016)
First-line Treatment for advanced Renal Cell Carcinoma A Phase 3, open-label, randomized Study of Atezolizumab (Anti-PD-L1-Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with untreated advanced Renal Cell Carcinoma (IMmotion) AN 37/15 of AUO
H. Rexer et al.
UROLOGE (2016)
Targeting membrane proteins for antibody discovery using phage display
Martina L. Jones et al.
SCIENTIFIC REPORTS (2016)
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
Helena Verdaguer et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Targeting CD73 in the tumor microenvironment with MEDI9447
Carl M. Hay et al.
ONCOIMMUNOLOGY (2016)
Filamentous Bacteriophage: Biology, Phage Display and Nanotechnology Applications
CURRENT ISSUES IN MOLECULAR BIOLOGY (2016)
Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo
Claire L. Dobson et al.
SCIENTIFIC REPORTS (2016)
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses
Italia Grenga et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2016)
Therapeutic Antibodies by Phage Display
Hyunbo Shim
CURRENT PHARMACEUTICAL DESIGN (2016)
Antibody Aggregation: Insights from Sequence and Structure
Wei Li et al.
ANTIBODIES (2016)
Phase I study of every 2-or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
E. G. Chiorean et al.
ANNALS OF ONCOLOGY (2015)
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
C. S. Fuchs et al.
ANNALS OF ONCOLOGY (2015)
Generation and analysis of the improved human HAL9/10 antibody phage display libraries
Jonas Kuegler et al.
BMC BIOTECHNOLOGY (2015)
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
Ali Roghanian et al.
CANCER CELL (2015)
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
Anna Hultberg et al.
CANCER RESEARCH (2015)
FDA Approval Summary: Ramucirumab for Gastric Cancer
Sandra J. Casak et al.
CLINICAL CANCER RESEARCH (2015)
Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Wan-Ching Yen et al.
CLINICAL CANCER RESEARCH (2015)
Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)
B. Besse et al.
EUROPEAN JOURNAL OF CANCER (2015)
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab
Ganesh Raghu et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Lisa M. Rice et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
A New Versatile Immobilization Tag Based on the Ultra High Affinity and Reversibility of the Calmodulin-Calmodulin Binding Peptide Interaction
Somnath Mukherjee et al.
JOURNAL OF MOLECULAR BIOLOGY (2015)
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Alexander Jarasch et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis
Weon Sup Lee et al.
MABS (2015)
Boosting antibody developability through rational sequence optimization
Daniel Seeliger et al.
MABS (2015)
Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform
Alex Klarenbeek et al.
MABS (2015)
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model
Michael D. Curley et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
VEGF mRNA and protein concentrations in the developing human eye
Irene T. Ma et al.
PEDIATRIC RESEARCH (2015)
FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity
Joshua Lehrer-Graiwer et al.
JACC-CARDIOVASCULAR IMAGING (2015)
Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration Animal Rule
Chia-Wei Tsai et al.
FRONTIERS IN MICROBIOLOGY (2015)
Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
Christoph Schliemann et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection
Alexandra Lavoisier et al.
MABS (2015)
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
Irene Brana et al.
TARGETED ONCOLOGY (2015)
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
Aurelien Amiot et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2015)
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma
Marc S. Raab et al.
BLOOD (2015)
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC)
Daniel Peter Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors.
Philippe G. Aftimos et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Building better monoclonal antibody-based therapeutics
George J. Weiner
NATURE REVIEWS CANCER (2015)
A phase 1 study investigating DX-2930 in healthy subjects
Yung Chyung et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2014)
Biopharmaceutical liquid formulation: a review of the science of protein stability and solubility in aqueous environments
Jordan W. Bye et al.
BIOTECHNOLOGY LETTERS (2014)
Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC
Christoph A. Schatz et al.
CANCER RESEARCH (2014)
Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2)
James V. Bready et al.
CANCER RESEARCH (2014)
High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency
C. Suffritti et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2014)
Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2014)
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer
Joachim von Pawel et al.
CLINICAL LUNG CANCER (2014)
Ramucirumab: First Global Approval
Raewyn M. Poole et al.
DRUGS (2014)
ADALIMUMAB IN THE TREATMENT OF IMMUNE-MEDIATED DISEASES
G. Lapadula et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2014)
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
Jon A. Kenniston et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Four individually druggable MET hotspots mediate HGF-driven tumor progression
Cristina Basilico et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF HEPATOLOGY (2014)
Antibody Phage Display: Technique and Applications
Christoph M. Hammers et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Estelle Lach-Trifilieff et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
Katrin Friedbichler et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Effector-Mediated Eradication of Precursor B Acute Lymphoblastic Leukemia with a Novel Fc-Engineered Monoclonal Antibody Targeting the BAFF-R
Reshmi Parameswaran et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
Karen Silence et al.
MABS (2014)
Drugs derived from phage display From candidate identification to clinical practice
Andrew E. Nixon et al.
MABS (2014)
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma
E Suzanne Cohen et al.
mAbs (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Phase 2 Trial of Cixutumumab in Children, Adolescents, and Young Adults With Refractory Solid Tumors: A Report From the Children's Oncology Group
Brenda Weigel et al.
PEDIATRIC BLOOD & CANCER (2014)
Antibody modeling assessment II. Structures and models
Alexey Teplyakov et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2014)
Anthrax lethal and edema toxins in anthrax pathogenesis
Shihui Liu et al.
TRENDS IN MICROBIOLOGY (2014)
Tailored Immune Responses: Novel Effector Helper T Cell Subsets in Protective Immunity
Ervin E. Kara et al.
PLOS PATHOGENS (2014)
A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Raxibacumab: potential role in the treatment of inhalational anthrax
Carlos E. Kummerfeldt
INFECTION AND DRUG RESISTANCE (2014)
Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?
Guilherme Rabinowits
CANCERS (2014)
A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
Nick Thatcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.
Karim Rihawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
A. L. Cohn et al.
ANNALS OF ONCOLOGY (2013)
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity
T. Hemmerle et al.
BRITISH JOURNAL OF CANCER (2013)
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen K. Sandhu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
J. R. Mackey et al.
CANCER RESEARCH (2013)
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Andrew P. Garner et al.
CANCER RESEARCH (2013)
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J. Pienta et al.
INVESTIGATIONAL NEW DRUGS (2013)
Discovery of diverse and functional antibodies from large human repertoire antibody libraries
Lauren J. Schwimmer et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2013)
The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
David A. Martin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties
Thomas Tiller et al.
MABS (2013)
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire
Brandon J. DeKosky et al.
NATURE BIOTECHNOLOGY (2013)
Protein selection using yeast surface display
Nimish Gera et al.
METHODS (2013)
Generating conformation-specific synthetic antibodies to trap proteins in selected functional states
Marcin Paduch et al.
METHODS (2013)
Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab
Frank J. Calzone et al.
PLOS ONE (2013)
A Novel Helper Phage Enabling Construction of Genome-Scale ORF-Enriched Phage Display Libraries
Amita Gupta et al.
PLOS ONE (2013)
Tumor Cell Expression of Vascular Endothelial Growth Factor Receptor 2 Is an Adverse Prognostic Factor in Patients with Squamous Cell Carcinoma of the Lung
Timothy R. Holzer et al.
PLOS ONE (2013)
The indistinguishability of epitopes from protein surface is explained by the distinct binding preferences of each of the six antigen-binding loops
Vered Kunik et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
Gian Luca Poli et al.
CANCER IMMUNOLOGY RESEARCH (2013)
The structural basis of antibody-antigen recognition
Inbal Sela-Culang et al.
FRONTIERS IN IMMUNOLOGY (2013)
Immunocytokines: a review of molecules in clinical development for cancer therapy
Thomas List et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
Psoriatic arthritis
Artur Jacek Sankowski et al.
POLISH JOURNAL OF RADIOLOGY (2013)
B-cell-depleting Therapy in Systemic Lupus Erythematosus
Manuel Ramos-Casals et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
M. Schmidt et al.
ANNALS OF ONCOLOGY (2012)
Development of Anti-Infectives Using Phage Display: Biological Agents against Bacteria, Viruses, and Parasites
Johnny X. Huang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Selection and characterization of cell binding and internalizing phage antibodies
Yu Zhou et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Engineering antibodies by yeast display
Eric T. Boder et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma
R. D. May et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Timothy S. Fisher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Targeting the EGFR signaling pathway in cancer therapy
Parthasarathy Seshacharyulu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Interleukin-23: as a drug target for autoimmune inflammatory diseases
Chunlei Tang et al.
IMMUNOLOGY (2012)
Antibody Phage Display Libraries: Contributions to Oncology
Carmela Dantas-Barbosa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bernd Bohrmann et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
Melinda S. Merchant et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Systematic Comparison of Free and Bound Antibodies Reveals Binding-Related Conformational Changes
Inbal Sela-Culang et al.
JOURNAL OF IMMUNOLOGY (2012)
Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
Paola A. Erba et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Blocking Agent Optimization for Nonspecific Binding on Phage Based Magnetoelastic Biosensors
Wen Shen et al.
JOURNAL OF THE ELECTROCHEMICAL SOCIETY (2012)
A strategy for risk mitigation of antibodies with fast clearance
Isidro Hoetzel et al.
MABS (2012)
Solubility evaluation of murine hybridoma antibodies
Stacey Spencer et al.
MABS (2012)
The discovery and development of belimumab: the anti-BLyS-lupus connection
William Stohl et al.
NATURE BIOTECHNOLOGY (2012)
The use of phage display to generate conformation-sensor recombinant antibodies
Aftabul Haque et al.
NATURE PROTOCOLS (2012)
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
Austin Gurney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Engineering Aggregation-Resistant Antibodies
Joseph M. Perchiacca et al.
ANNUAL REVIEW OF CHEMICAL AND BIOMOLECULAR ENGINEERING, VOL 3 (2012)
Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression
Nikhil C. Munshi et al.
BLOOD (2012)
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs
Hans Ulrichts et al.
BLOOD (2011)
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
B. E. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays
Conrad E. Z. Chan et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
HuCAL PLATINUM, a Synthetic Fab Library Optimized for Sequence Diversity and Superior Performance in Mammalian Expression Systems
Josef Prassler et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Application of a High-Throughput Screening Procedure with PEG-Induced Precipitation to Compare Relative Protein Solubility During Formulation Development with IgG1 Monoclonal Antibodies
Todd J. Gibson et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Phage Display for the Generation of Antibodies for Proteome Research, Diagnostics and Therapy
Thomas Schirrmann et al.
MOLECULES (2011)
Antibodies for biodefense
Jeffrey W. Froude et al.
MABS (2011)
A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and-23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis
Timothy L. Vollmer et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Selection of antibodies against a single rare cell present in a heterogeneous population using phage display
Morten Drby Sorensen et al.
NATURE PROTOCOLS (2011)
Human TH17 Cells Are Long-Lived Effector Memory Cells
Ilona Kryczek et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Association Between Environmental Factors and Onset of Psoriatic Arthritis in Patients With Psoriasis
Lihi Eder et al.
ARTHRITIS CARE & RESEARCH (2011)
Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration
R. Blake Pepinsky et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Two-Step in Vitro Antibody Affinity Maturation Enables Estradiol-17β Assays with More than 10-Fold Higher Sensitivity
Norihiro Kobayashi et al.
ANALYTICAL CHEMISTRY (2010)
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
M. Schmidt et al.
ANNALS OF ONCOLOGY (2010)
Effect of Long-Term Belimumab Treatment on B Cells in Systemic Lupus Erythematosus
Annett M. Jacobi et al.
ARTHRITIS AND RHEUMATISM (2010)
Phage display: Concept, innovations, applications and future
Jyoti Pande et al.
BIOTECHNOLOGY ADVANCES (2010)
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
A. Younes et al.
BRITISH JOURNAL OF CANCER (2010)
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
T. Trarbach et al.
BRITISH JOURNAL OF CANCER (2010)
Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6
E. LEGOUFFE et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Neil R. Smith et al.
CLINICAL CANCER RESEARCH (2010)
A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Bart Kuenen et al.
CLINICAL CANCER RESEARCH (2010)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
Manfred Johannsen et al.
EUROPEAN JOURNAL OF CANCER (2010)
Microselection - affinity selecting antibodies against a single rare cell in a heterogeneous population
Morten Draeby Sørensen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Phase II-study of PRO95780 plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL)
S. Wittebol et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies
Martina L. Jones et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Prediction of Aggregation Prone Regions of Therapeutic Proteins
Naresh Chennamsetty et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2010)
Development of a novel mammalian cell surface antibody display platform
Chen Zhou et al.
MABS (2010)
Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
David M. Brown et al.
OPHTHALMOLOGY (2010)
Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy
Norbert Marschner et al.
UROLOGIA INTERNATIONALIS (2010)
Innate IL-17-producing cells: the sentinels of the immune system
Daniel J. Cua et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
Monica Else et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
Ralph F. Alderson et al.
CLINICAL CANCER RESEARCH (2009)
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
Zehra Kaymakcalan et al.
CLINICAL IMMUNOLOGY (2009)
Interaction of antibodies with ErbB receptor extracellular regions
Karl R. Schmitz et al.
EXPERIMENTAL CELL RESEARCH (2009)
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Michael P. Cancro et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
Leslie van der Fits et al.
JOURNAL OF IMMUNOLOGY (2009)
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
Pedro J. Beltran et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Raxibacumab for the Treatment of Inhalational Anthrax.
Thi-Sau Migone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Design of therapeutic proteins with enhanced stability
Naresh Chennamsetty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens
C. Lloyd et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2009)
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
Birgit Schoeberl et al.
SCIENCE SIGNALING (2009)
In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology
Josef Prassler et al.
IMMUNOTHERAPY (2009)
Rapid isolation of intrabody candidates by using an optimized non-immune phage antibody library
K. Nagano et al.
PHARMAZIE (2009)
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis
Alexa B. Kimball et al.
ARCHIVES OF DERMATOLOGY (2008)
Epidermal growth factor receptor immunohistochemistry - Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
Fred R. Hirsch et al.
CANCER (2008)
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
C. Adams et al.
CELL DEATH AND DIFFERENTIATION (2008)
Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
Jessica Marlind et al.
CLINICAL CANCER RESEARCH (2008)
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo
Alessandra Villa et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Human Anti-gold Antibodies BIOFUNCTIONALIZATION OF GOLD NANOPARTICLES AND SURFACES WITH ANTI-GOLD ANTIBODIES
Hideki Watanabe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells
Amara C. Siva et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Engineering Antibody Heavy Chain CDR3 to Create a Phage Display Fab Library Rich in Antibodies That Bind Charged Carbohydrates
Sonia Schoonbroodt et al.
JOURNAL OF IMMUNOLOGY (2008)
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody
Zhongyu Zhu et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
An entirely cell-based system to generate single-chain antibodies against cell surface receptors
Barbara D. Lipes et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies
Christine Rothe et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Measuring and increasing protein solubility
Saul R. Trevino et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification
Stefan Steidl et al.
MOLECULAR IMMUNOLOGY (2008)
Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: Functional and structural correlates
Emanuela Pappalardo et al.
MOLECULAR IMMUNOLOGY (2008)
Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity
Casim A. Sarkar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Isolation of human monoclonal antibodies by mammalian cell display
Roger R. Beerli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A step-wise approach significantly enhances protein yield of a rationally-designed agonist antibody fragment in E-coli
Bing Lin et al.
PROTEIN EXPRESSION AND PURIFICATION (2008)
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
Shiqing Li et al.
STRUCTURE (2008)
Pharmacokinetics of intravitreal ranibizumab (Lucentis)
Sophie J. Bakri et al.
OPHTHALMOLOGY (2007)
High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries
Frederic A. Fellouse et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Properties, production, and applications of camelid single-domain antibody fragments
M. M. Harmsen et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2007)
Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits
Jacques Gaudreault et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2007)
Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies
Yoshiko Akamatsu et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Codon engineering for improved antibody expression in mammalian cells
Jill M. Carton et al.
PROTEIN EXPRESSION AND PURIFICATION (2007)
IMC-A12, a human IgG, monoclonal antibody to the insulin-like growth factor I receptor
Eric K. Rowinsky et al.
CLINICAL CANCER RESEARCH (2007)
Generation of activation-specific human anti-αMβ2 single-chain antibodies as potential diagnostic tools and therapeutic agents
Steffen U. Eisenhardt et al.
BLOOD (2007)
IFN-γ enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3
Carmelo Carlo-Stella et al.
CANCER RESEARCH (2007)
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF
Eva-Maria Krinner et al.
MOLECULAR IMMUNOLOGY (2007)
Application of phage display to high throughput antibody generation and characterization
Darren J. Schofield et al.
GENOME BIOLOGY (2007)
Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules
Steffen U. Eisenhardt et al.
NATURE PROTOCOLS (2007)
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies
Carlos Vaccaro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A potent human anti-eotaxin1 antibody, CAT-213: Isolation by phage display and in vitro and in vivo efficacy
Sarah Main et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity
M. P. Cancro
ANNALS OF THE RHEUMATIC DISEASES (2006)
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration
Eva-Maria Krinner et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Selection of tumor-binding ligands in cancer patients with phage display libraries
David N. Krag et al.
CANCER RESEARCH (2006)
Conformation-specific blockade of the integrin GPIIb/IIIa - A novel antiplatelet strategy that selectively targets activated platelets
Meike Schwarz et al.
CIRCULATION RESEARCH (2006)
Affinity maturation of phage display antibody populations using ribosome display
Maria Groves et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2006)
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells
Mitchell Ho et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor
G Dewald et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Probing a protein-protein interaction by in vitro evolution
George Thom et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C
Simon S. Brack et al.
CLINICAL CANCER RESEARCH (2006)
High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays
D Wassaf et al.
ANALYTICAL BIOCHEMISTRY (2006)
Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization
LH Huang et al.
ANALYTICAL BIOCHEMISTRY (2006)
The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined Immunodeficient mice
C Carlo-Stella et al.
CANCER RESEARCH (2006)
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies
ZY Zhu et al.
JOURNAL OF VIROLOGY (2006)
Effects of protein aggregates: An immunologic perspective
Amy S. Rosenberg
AAPS JOURNAL (2006)
The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects
O Shimozato et al.
IMMUNOLOGY (2006)
Filamentous phage display in the new millennium
JW Kehoe et al.
CHEMICAL REVIEWS (2005)
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages
LE Harrington et al.
NATURE IMMUNOLOGY (2005)
Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants
ABH Bakker et al.
JOURNAL OF VIROLOGY (2005)
The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries
RA Kramer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The ErbB receptors and their ligands in cancer: An overview
N Normanno et al.
CURRENT DRUG TARGETS (2005)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac et al.
BRITISH JOURNAL OF CANCER (2005)
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA
ES Day et al.
BIOCHEMISTRY (2005)
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
N Prang et al.
BRITISH JOURNAL OF CANCER (2005)
The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies
A Menendez et al.
ANALYTICAL BIOCHEMISTRY (2005)
Human antibodies from transgenic animals
N Lonberg
NATURE BIOTECHNOLOGY (2005)
Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome
F Lavie et al.
JOURNAL OF PATHOLOGY (2004)
Production of a human single-chain variable fragment antibody against esophageal carcinoma
Ming-Yan Xu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Establishment of FUT8 knockout Chinese hamster ovary cells:: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity
N Yamane-Ohnuki et al.
BIOTECHNOLOGY AND BIOENGINEERING (2004)
Single-chain antibodies for the conformation-specific blockade of activated platelet integrin αIIbβ3 designed by subtractive selection from naive human phage libraries
M Schwarz et al.
FASEB JOURNAL (2004)
Antibodies from phage antibody libraries
ARM Bradbury et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Generation and characterization of single-chain antibody fragments specific against transmembrane envelope glycoprotein gp46 of maedi-visna virus
D Blazek et al.
JOURNAL OF VIROLOGICAL METHODS (2004)
von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura
F Peyvandi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in caucasian and chinese hans population
GS Sagoo et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C
K Persaud et al.
JOURNAL OF CELL SCIENCE (2004)
Selective targeted delivery of TNFα to tumor blood vessels
L Borsi et al.
BLOOD (2003)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
KP Baker et al.
ARTHRITIS AND RHEUMATISM (2003)
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3
R Rauchenberger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells
L Gorelik et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
G-CSF-stimulated neutrophils are a prominent source of functional BLyS
P Scapini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The production and application of single-chain antibody fragments
D Blazek et al.
FOLIA MICROBIOLOGICA (2003)
Anthrax toxin: a tripartite lethal combination
P Ascenzi et al.
FEBS LETTERS (2002)
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin
L Borsi et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival
AJ Novak et al.
BLOOD (2002)
Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation
JI Henter et al.
BLOOD (2002)
Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells
ZA Nagy et al.
NATURE MEDICINE (2002)
Therapeutic applications of monoclonal antibodies
M Berger et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2002)
Anthrax as a biological weapon, 2002 - Updated recommendations for management
TV Inglesby et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy
D Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
Engineering M13 for phage display
SS Sidhu
BIOMOLECULAR ENGINEERING (2001)
Anti-self antibodies selected from a human IgD heavy chain repertoire:: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens
T Raum et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)
A helper phage to improve single-chain antibody presentation in phage display
S Rondot et al.
NATURE BIOTECHNOLOGY (2001)
Synthesis and release of B-lymphocyte stimulator from myeloid cells
B Nardelli et al.
BLOOD (2001)
Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries
E Söderlind et al.
NATURE BIOTECHNOLOGY (2000)
Diversity in the CDR3 region of VH is sufficient for most antibody specificities
JL Xu et al.
IMMUNITY (2000)
High copy display of large proteins on phage for functional selections
SS Sidhu et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
A Knappik et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
分享论文
